NCT02272634View on ClinicalTrials.gov

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 4, 2015

Primary Completion Date

November 8, 2017

Study Completion Date

November 8, 2017

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

YPL-001 80 mg

twice daily \[BID\]

DRUG

YPL-001 160 mg

twice daily \[BID\]

DRUG

Placebo

twice daily \[BID\]

Trial Locations (4)

32789

Florida Pulmonary Research Institute, LLC, Winter Park

35249

UAB Lung Health Center, Birmingham

43213

Aventiv Research Inc., Columbus

191140

Temple Lung Center, Temple University Hospital, Philadelphia

All Listed Sponsors
lead

Yungjin Pharm. Co., Ltd.

INDUSTRY

NCT02272634 - A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients | Biotech Hunter | Biotech Hunter